Novo Nordisk ups forecasts after Q1 profit boostAfter an indifferent period Novo Nordisk has kicked off 2021 on the front foot, raising its financial forecast Share XNovo Nordisk ups forecasts after Q1 profit boosthttps://pharmaphorum.com/news/novo-nordisk-ups-forecasts-after-q1-profit-boost/
Gilead pushes on with NASH partnership with Novo NordiskGilead is one of many pharmas chasing mega-bucks promised by the fatty liver disease known as NASH – Share XGilead pushes on with NASH partnership with Novo Nordiskhttps://pharmaphorum.com/news/gilead-pushes-on-with-nash-partnership-with-novo-nordisk/
Novo Nordisk’s semaglutide effective against obesity in new trialNovo Nordisk’s hopes of getting semaglutide approved for obesity management may have received a boost, with a new, Share XNovo Nordisk’s semaglutide effective against obesity in new trialhttps://pharmaphorum.com/news/novo-nordisks-semaglutide-effective-obesity-new-trial/
High hopes as Inventiva takes NASH contender into phase 3Analysts are continuing to back Inventiva’s lanifibranor as a potential “best-in-class” drug for the fatty liver disease NASH, Share XHigh hopes as Inventiva takes NASH contender into phase 3https://pharmaphorum.com/news/high-hopes-as-inventiva-takes-nash-contender-into-phase-3/
Novo Nordisk’s gene silencing alliance with Dicerna bears first fruitTwo years after starting to work together, Novo Nordisk and Dicerna have selected the first candidate from a Share XNovo Nordisk’s gene silencing alliance with Dicerna bears first fruithttps://pharmaphorum.com/news/novo-nordisks-gene-silencing-alliance-with-dicerna-bears-first-fruit/
Lilly surges on positive phase 3 readout from diabetes contenderEli Lilly’s decision to throw large amounts of research dollars at its next-generation diabetes drug tirzepatide could be Share XLilly surges on positive phase 3 readout from diabetes contenderhttps://pharmaphorum.com/news/lilly-surges-on-positive-phase-3-readout-from-diabetes-contender/
Gilead and Novo plot next steps after trial data from NASH comboGilead and Novo Nordisk have announced their drug combinations for the fatty liver disease known as NASH checked Share XGilead and Novo plot next steps after trial data from NASH combohttps://pharmaphorum.com/news/gilead-and-novo-plot-next-steps-after-encouraging-data-from-nash-combo/
Towards a new understanding of cardiovascular risk in diabetesA new post-hoc analysis from Novo Nordisk of their SUSTAIN 6 and PIONEER 6 studies into semaglutide is Share XTowards a new understanding of cardiovascular risk in diabeteshttps://pharmaphorum.com/r-d/views-analysis-r-d/towards-a-new-understanding-of-cardiovascular-risk-in-diabetes/
Novo Nordisk to buy Emisphere and diabetes pill tech for $1.8bnNovo Nordisk has agreed to buy Emisphere Technologies for $1.8 billion, as it continues its quest to develop Share XNovo Nordisk to buy Emisphere and diabetes pill tech for $1.8bnhttps://pharmaphorum.com/news/novo-nordisk-to-buy-emisphere-and-diabetes-pill-tech-for-1-8bn/
